Literature DB >> 3382592

Enantioselectivity of 4-hydroxylation in extensive and poor metabolizers of debrisoquine.

M Eichelbaum1, L Bertilsson, A Küpfer, E Steiner, C O Meese.   

Abstract

Debrisoquine (DQ) has no chiral centre, but hydroxylation in position 4 leads to formation of an asymmetric carbon centre with two possible enantiomers, their absolute configuration being R(-) and S(+)-4-hydroxydebrisoquine (4-OHDQ). Since the absolute stereochemistry of the 4-hydroxylation of DQ in man is unknown, the enantioselectivity of this process was studied in panels of extensive (EM) and poor metabolizers (PM) of DQ. In EM subjects 4-hydroxylation of DQ leads almost exclusively to the formation of S(+)-4-OHDQ. In contrast, PM subjects were not only characterized by a decreased total 4-OHDQ formation but also a marked loss of enantioselectivity in product formation. Between 5 to 36% of total 4-OHDQ was excreted as R(-)-4-OHDQ.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3382592      PMCID: PMC1387813          DOI: 10.1111/j.1365-2125.1988.tb03335.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  19 in total

1.  High-performance liquid chromatographic method for the analysis of debrisoquine and its S-(+)- and R-(-)-hydroxy metabolites in urine.

Authors:  C O Meese; P Thalheimer; M Eichelbaum
Journal:  J Chromatogr       Date:  1987-12-25

2.  Comparative pharmacogenetics of sparteine and debrisoquine.

Authors:  T Inaba; A Vinks; S V Otton; W Kalow
Journal:  Clin Pharmacol Ther       Date:  1983-03       Impact factor: 6.875

3.  Polymorphic oxidation of sparteine and debrisoquine: related pharmacogenetic entities.

Authors:  M Eichelbaum; L Bertilsson; J Säwe; C Zekorn
Journal:  Clin Pharmacol Ther       Date:  1982-02       Impact factor: 6.875

4.  Polymorphic hydroxylation of debrisoquine.

Authors:  G T Tucker; J H Silas; A O Iyun; M S Lennard; A J Smith
Journal:  Lancet       Date:  1977-10-01       Impact factor: 79.321

5.  A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.

Authors:  D A Evans; A Mahgoub; T P Sloan; J R Idle; R L Smith
Journal:  J Med Genet       Date:  1980-04       Impact factor: 6.318

6.  Animal modelling of human polymorphic drug oxidation--the metabolism of debrisoquine and phenacetin in rat inbred strains.

Authors:  S G Al-Dabbagh; J R Idle; R L Smith
Journal:  J Pharm Pharmacol       Date:  1981-03       Impact factor: 3.765

7.  The metabolism of [14C]-debrisoquine in man.

Authors:  J R Idle; A Mahgoub; M M Angelo; L G Dring; R Lancaster; R L Smith
Journal:  Br J Clin Pharmacol       Date:  1979-03       Impact factor: 4.335

8.  Metabolism of debrisoquine sulphate in rat, dog and man.

Authors:  J G Allen; A N Brown; T R Marten
Journal:  Xenobiotica       Date:  1976-07       Impact factor: 1.908

9.  Antipyrine metabolism in relation to polymorphic oxidations of sparteine and debrisoquine.

Authors:  M Eichelbaum; L Bertilsson; J Säwe
Journal:  Br J Clin Pharmacol       Date:  1983-03       Impact factor: 4.335

10.  [Drug hydroxylation disorders (debrisoquin type) in a random sample of the Swiss population].

Authors:  B Dick; A Küpfer; J Molnàr; S Braunschweig; R Preisig
Journal:  Schweiz Med Wochenschr       Date:  1982-07-24
View more
  2 in total

Review 1.  Recent developments in hepatic drug oxidation. Implications for clinical pharmacokinetics.

Authors:  K Brosen
Journal:  Clin Pharmacokinet       Date:  1990-03       Impact factor: 6.447

2.  Stereoselective disposition of flecainide in relation to the sparteine/debrisoquine metaboliser phenotype.

Authors:  A S Gross; G Mikus; C Fischer; R Hertrampf; U Gundert-Remy; M Eichelbaum
Journal:  Br J Clin Pharmacol       Date:  1989-11       Impact factor: 4.335

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.